A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Recruiting · NCT07572006 · Registry updated 2026-09-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Recruiting | Phase 1 | 2026-09-25 | NCT07572006 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Janssen Research & Development, LLC | 188 |
16 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Aarhus University Hospital | Aarhus N | Denmark | 3 |
| CHRU Tours Hopital Bretonneau | Tours | France | 4 |
| CHU Lyon Sud | Pierre-Bénite | France | 13 |
| Clinica Univ. de Navarra | Pamplona | Spain | 42 |
| Hosp Univ Fund Jimenez Diaz | Madrid | Spain | 33 |
| Indiana Blood & Marrow Transplantation | Indianapolis | United States | 2 |
| Institut Claudius Regaud | Toulouse | France | 40 |
| Institut Paoli Calmettes | Marseille | France | 56 |
| MD Anderson Cancer Center - University of Texas | Houston | United States | 4 |
| NYU Langone Health | New York | United States | 403 |
| Peter MacCallum Cancer Centre | Melbourne | Australia | 32 |
| Rutgers Cancer Institute of New Jersey | Piscataway | United States | 3 |
| Sarah Cannon Cancer Institute | Nashville | United States | 3 |
| START Midwest | Grand Rapids | United States | 79 |
| The Christie NHS Foundation Trust | Manchester | United Kingdom | 113 |
| UZ Antwerpen | Edegem | Belgium | 32 |